ArticleAlimentary pharmacology & therapeutics2026
Baseline HDV-RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline HDV-RNA Levels Could Stratify Clinical Risk Before, But Not After, Cirrhosis in Chronic Hepatitis D: A Multicentre European Study.Alimentary pharmacology & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND AND
aimsChronic hepatitis D (CHD) is associated with rapid progression to liver cirrhosis. However, the prognostic relevance of quantitative serum HDV-RNA remains incompletely defined. We aimed to evaluate whether baseline HDV-RNA levels are associated with the risk of liver-related events in untreated patients with CHD and to validate these findings in two independent European cohorts.
methodsWe conducted a multicentre retrospective-prospective cohort study including 260 untreated adults with CHD and detectable HDV-RNA. Patients were derived from a Spanish derivation cohort (n = 98) and two Italian validation cohorts (n = 100 and n = 62). Baseline serum qHDV-RNA was categorized in 1-log increments starting from 6 IU/mL.
resultsDuring a median follow-up of 4.1 years, 74 patients (28%) experienced at least one liver-related event, with a significantly higher incidence in patients with cirrhosis than in those without cirrhosis (p < 0.001). Among noncirrhotic patients, increasing baseline HDV-RNA levels were consistently associated with a higher proportion of liver-related events across derivation and validation cohorts, whereas no events occurred at the lowest HDV-RNA category. In contrast, among patients with established cirrhosis, baseline HDV-RNA levels were not associated with the occurrence of liver-related events, and cumulative incidence was comparable across viral load categories.
conclusionsBaseline quantitative HDV-RNA allows early risk stratification in untreated patients with chronic hepatitis D before the development of liver cirrhosis. Once cirrhosis is established, clinical outcomes are largely independent of viral replication, emphasising the need to prioritise timely antiviral intervention and close surveillance at earlier disease stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.